Evidence map›Paper›PMID 40587431›Full record

ArticlePloS one2025

Improving a data mining based diagnostic support tool for rare diseases on the example of M. Fabry: Gender differences need to be taken into account.

Philipp Hahn, Werner Lechner, Rainer-Georg Siefen, Christina Lampe, Peter Nordbeck, Lorenz Grigull, Thomas Lücke

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Philipp HahnUniversity Children's Hospital, Ruhr-University Bochum, Bochum, Germany.ORCID 0009-0007-4354-6475
Werner LechnerKIMedi GmbH, Ulm, Germany.
Rainer-Georg SiefenUniversity Children's Hospital, Ruhr-University Bochum, Bochum, Germany.
Christina LampeZSEGI Centre for Rare Diseases of the University Hospital Gießen, Gießen, Germany.
Peter NordbeckFaZiT Fabry Centre for interdisciplinary therapy of the University Hospital Würzburg, Würzburg, Germany.
Lorenz GrigullZSEB Centre for rare diseases of the University Hospital Bonn, Bonn, Germany.
Thomas LückeUniversity Children's Hospital, Ruhr-University Bochum, Bochum, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRare diseases often present with a variety of clinical symptoms and therefore are challenging to diagnose. Fabry disease is an x-linked rare metabolic disorder. The severity of symptoms is usually different in men and women. Since therapeutic options for Fabry disease exist, early diagnosis is important. An artificial intelligence (AI)-based diagnosis support algorithm for rare diseases has been developed in preliminary studies.

objectiveOur aim was to extend and train the questionnaire-based AI, capable of distinguishing patients with from those without rare diseases, to achieve satisfactory sensitivity for the detection of a single rare disease, Fabry disease, taking into account gender differences in disease perception.

methodsWe collected 33 complete datasets from patients with confirmed Fabry disease. These records contained answered AI questionnaires, general information on disease progression, demographic information and quality of life (QoL) measures. The AI was trained to distinguish patients with Fabry disease from patients with relevant differential diagnoses. Its performance was assayed using stratified eleven-fold cross-validation and ROC curve calculation. Variables influencing the performance of the AI were examined with linear regression and calculation of the coefficient of determination.

resultWe were able to show that a relatively small sample is sufficient to achieve a sensitivity of 88.12% for the presence of Fabry disease, taking into account gender-specific differences in the disease perception during the pre-diagnostic phase. No confounders of the tool's performance could be found in the data collected concerning the patients' quality of life and diagnostic history.

conclusionThis study illustrates on the example of Fabry disease that differences between female and male Fabry patients, not only in the expression of symptoms, but also with regard to disease perception, might be relevant influencing variables for improving the performance of AI-based diagnostic support tools for rare diseases.

Indexed as

Data MiningFabry DiseaseRare DiseasesAdultAgedAlgorithmsArtificial IntelligenceFemaleHumansMaleMiddle AgedQuality of LifeROC CurveSex FactorsSurveys and Questionnaires

Identifiers

PMID40587431
PMCPMC12208464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.